|
Gene: MAP3K2 |
Gene summary for MAP3K2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | MAP3K2 | Gene ID | 10746 |
Gene name | mitogen-activated protein kinase kinase kinase 2 | |
Gene Alias | MEKK2 | |
Cytomap | 2q14.3 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | A0A024RAH0 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10746 | MAP3K2 | CA_HPV_1 | Human | Cervix | CC | 2.89e-03 | 7.99e-02 | 0.0264 |
10746 | MAP3K2 | CCI_2 | Human | Cervix | CC | 1.91e-04 | 5.86e-01 | 0.5249 |
10746 | MAP3K2 | CCI_3 | Human | Cervix | CC | 3.69e-03 | 4.89e-01 | 0.516 |
10746 | MAP3K2 | CCII_1 | Human | Cervix | CC | 2.50e-03 | -3.37e-01 | 0.3249 |
10746 | MAP3K2 | L1 | Human | Cervix | CC | 7.87e-06 | -2.84e-01 | 0.0802 |
10746 | MAP3K2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 7.38e-03 | -4.09e-01 | 0.0155 |
10746 | MAP3K2 | HTA11_347_2000001011 | Human | Colorectum | AD | 8.21e-04 | 3.02e-01 | -0.1954 |
10746 | MAP3K2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 4.56e-04 | -3.53e-01 | 0.0674 |
10746 | MAP3K2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 6.85e-08 | -3.43e-01 | 0.3005 |
10746 | MAP3K2 | A015-C-203 | Human | Colorectum | FAP | 2.04e-23 | -3.20e-01 | -0.1294 |
10746 | MAP3K2 | A015-C-204 | Human | Colorectum | FAP | 1.99e-03 | -3.14e-01 | -0.0228 |
10746 | MAP3K2 | A014-C-040 | Human | Colorectum | FAP | 9.46e-05 | -5.74e-01 | -0.1184 |
10746 | MAP3K2 | A002-C-201 | Human | Colorectum | FAP | 3.06e-13 | -4.01e-01 | 0.0324 |
10746 | MAP3K2 | A002-C-203 | Human | Colorectum | FAP | 3.73e-04 | -2.04e-01 | 0.2786 |
10746 | MAP3K2 | A001-C-119 | Human | Colorectum | FAP | 4.48e-07 | -4.30e-01 | -0.1557 |
10746 | MAP3K2 | A001-C-108 | Human | Colorectum | FAP | 1.06e-14 | -3.01e-01 | -0.0272 |
10746 | MAP3K2 | A002-C-205 | Human | Colorectum | FAP | 2.69e-18 | -4.57e-01 | -0.1236 |
10746 | MAP3K2 | A001-C-104 | Human | Colorectum | FAP | 2.64e-05 | -2.81e-01 | 0.0184 |
10746 | MAP3K2 | A015-C-005 | Human | Colorectum | FAP | 9.53e-03 | -2.96e-01 | -0.0336 |
10746 | MAP3K2 | A015-C-006 | Human | Colorectum | FAP | 1.37e-11 | -4.59e-01 | -0.0994 |
Page: 1 2 3 4 5 6 7 8 9 10 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00109486 | Thyroid | PTC | negative regulation of cell cycle process | 122/5968 | 294/18723 | 2.94e-04 | 2.08e-03 | 122 |
GO:19019885 | Thyroid | PTC | negative regulation of cell cycle phase transition | 104/5968 | 249/18723 | 6.01e-04 | 3.82e-03 | 104 |
GO:000725419 | Thyroid | PTC | JNK cascade | 73/5968 | 167/18723 | 8.41e-04 | 5.17e-03 | 73 |
GO:00070936 | Thyroid | PTC | mitotic cell cycle checkpoint | 58/5968 | 129/18723 | 1.22e-03 | 6.97e-03 | 58 |
GO:00000756 | Thyroid | PTC | cell cycle checkpoint | 72/5968 | 169/18723 | 2.09e-03 | 1.11e-02 | 72 |
GO:00000777 | Thyroid | PTC | DNA damage checkpoint | 50/5968 | 115/18723 | 5.79e-03 | 2.61e-02 | 50 |
GO:00447736 | Thyroid | PTC | mitotic DNA damage checkpoint | 37/5968 | 81/18723 | 6.35e-03 | 2.79e-02 | 37 |
GO:00447746 | Thyroid | PTC | mitotic DNA integrity checkpoint | 38/5968 | 85/18723 | 8.78e-03 | 3.66e-02 | 38 |
GO:000734622 | Thyroid | ATC | regulation of mitotic cell cycle | 236/6293 | 457/18723 | 7.58e-16 | 5.92e-14 | 236 |
GO:0071496210 | Thyroid | ATC | cellular response to external stimulus | 165/6293 | 320/18723 | 2.01e-11 | 7.23e-10 | 165 |
GO:200102026 | Thyroid | ATC | regulation of response to DNA damage stimulus | 121/6293 | 219/18723 | 3.22e-11 | 1.08e-09 | 121 |
GO:007121427 | Thyroid | ATC | cellular response to abiotic stimulus | 169/6293 | 331/18723 | 3.24e-11 | 1.08e-09 | 169 |
GO:010400427 | Thyroid | ATC | cellular response to environmental stimulus | 169/6293 | 331/18723 | 3.24e-11 | 1.08e-09 | 169 |
GO:004578719 | Thyroid | ATC | positive regulation of cell cycle | 158/6293 | 313/18723 | 4.18e-10 | 1.14e-08 | 158 |
GO:190198715 | Thyroid | ATC | regulation of cell cycle phase transition | 187/6293 | 390/18723 | 2.36e-09 | 5.61e-08 | 187 |
GO:007147825 | Thyroid | ATC | cellular response to radiation | 101/6293 | 186/18723 | 4.67e-09 | 1.04e-07 | 101 |
GO:000931426 | Thyroid | ATC | response to radiation | 210/6293 | 456/18723 | 1.69e-08 | 3.39e-07 | 210 |
GO:004578614 | Thyroid | ATC | negative regulation of cell cycle | 181/6293 | 385/18723 | 2.64e-08 | 5.07e-07 | 181 |
GO:0010212110 | Thyroid | ATC | response to ionizing radiation | 82/6293 | 148/18723 | 3.88e-08 | 7.15e-07 | 82 |
GO:007147927 | Thyroid | ATC | cellular response to ionizing radiation | 46/6293 | 72/18723 | 1.41e-07 | 2.30e-06 | 46 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0491212 | Cervix | CC | GnRH signaling pathway | 26/1267 | 93/8465 | 8.72e-04 | 3.87e-03 | 2.29e-03 | 26 |
hsa040109 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
hsa04540 | Cervix | CC | Gap junction | 22/1267 | 88/8465 | 9.07e-03 | 2.85e-02 | 1.69e-02 | 22 |
hsa0491213 | Cervix | CC | GnRH signaling pathway | 26/1267 | 93/8465 | 8.72e-04 | 3.87e-03 | 2.29e-03 | 26 |
hsa0401012 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
hsa045401 | Cervix | CC | Gap junction | 22/1267 | 88/8465 | 9.07e-03 | 2.85e-02 | 1.69e-02 | 22 |
hsa04912 | Colorectum | AD | GnRH signaling pathway | 35/2092 | 93/8465 | 3.69e-03 | 1.90e-02 | 1.21e-02 | 35 |
hsa049121 | Colorectum | AD | GnRH signaling pathway | 35/2092 | 93/8465 | 3.69e-03 | 1.90e-02 | 1.21e-02 | 35 |
hsa049126 | Colorectum | FAP | GnRH signaling pathway | 28/1404 | 93/8465 | 8.16e-04 | 5.14e-03 | 3.13e-03 | 28 |
hsa04010 | Colorectum | FAP | MAPK signaling pathway | 68/1404 | 302/8465 | 4.00e-03 | 1.67e-02 | 1.02e-02 | 68 |
hsa049127 | Colorectum | FAP | GnRH signaling pathway | 28/1404 | 93/8465 | 8.16e-04 | 5.14e-03 | 3.13e-03 | 28 |
hsa040101 | Colorectum | FAP | MAPK signaling pathway | 68/1404 | 302/8465 | 4.00e-03 | 1.67e-02 | 1.02e-02 | 68 |
hsa049128 | Colorectum | CRC | GnRH signaling pathway | 25/1091 | 93/8465 | 2.11e-04 | 2.71e-03 | 1.84e-03 | 25 |
hsa040102 | Colorectum | CRC | MAPK signaling pathway | 56/1091 | 302/8465 | 2.76e-03 | 1.77e-02 | 1.20e-02 | 56 |
hsa049129 | Colorectum | CRC | GnRH signaling pathway | 25/1091 | 93/8465 | 2.11e-04 | 2.71e-03 | 1.84e-03 | 25 |
hsa040103 | Colorectum | CRC | MAPK signaling pathway | 56/1091 | 302/8465 | 2.76e-03 | 1.77e-02 | 1.20e-02 | 56 |
hsa040108 | Lung | IAC | MAPK signaling pathway | 62/1053 | 302/8465 | 3.54e-05 | 6.38e-04 | 4.24e-04 | 62 |
hsa0491210 | Lung | IAC | GnRH signaling pathway | 20/1053 | 93/8465 | 9.36e-03 | 3.62e-02 | 2.41e-02 | 20 |
hsa0401011 | Lung | IAC | MAPK signaling pathway | 62/1053 | 302/8465 | 3.54e-05 | 6.38e-04 | 4.24e-04 | 62 |
hsa0491211 | Lung | IAC | GnRH signaling pathway | 20/1053 | 93/8465 | 9.36e-03 | 3.62e-02 | 2.41e-02 | 20 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAP3K2 | SNV | Missense_Mutation | c.1550N>T | p.Gly517Val | p.G517V | Q9Y2U5 | protein_coding | deleterious(0) | possibly_damaging(0.566) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
MAP3K2 | SNV | Missense_Mutation | c.1210N>A | p.Glu404Lys | p.E404K | Q9Y2U5 | protein_coding | tolerated(0.1) | benign(0.348) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
MAP3K2 | SNV | Missense_Mutation | novel | c.928N>G | p.Thr310Ala | p.T310A | Q9Y2U5 | protein_coding | tolerated(0.41) | benign(0.003) | TCGA-HN-A2NL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
MAP3K2 | SNV | Missense_Mutation | novel | c.832A>G | p.Asn278Asp | p.N278D | Q9Y2U5 | protein_coding | tolerated(0.17) | benign(0.044) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MAP3K2 | SNV | Missense_Mutation | novel | c.883N>G | p.Leu295Val | p.L295V | Q9Y2U5 | protein_coding | deleterious(0.02) | benign(0) | TCGA-VS-A8EL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MAP3K2 | SNV | Missense_Mutation | c.987N>T | p.Arg329Ser | p.R329S | Q9Y2U5 | protein_coding | tolerated(0.18) | benign(0.071) | TCGA-AA-3494-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folinic | PR | |
MAP3K2 | SNV | Missense_Mutation | novel | c.740T>G | p.Phe247Cys | p.F247C | Q9Y2U5 | protein_coding | tolerated(0.26) | benign(0.005) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAP3K2 | SNV | Missense_Mutation | c.1601G>A | p.Ser534Asn | p.S534N | Q9Y2U5 | protein_coding | tolerated(0.56) | benign(0.066) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |
MAP3K2 | SNV | Missense_Mutation | rs376189453 | c.1018G>A | p.Val340Ile | p.V340I | Q9Y2U5 | protein_coding | tolerated(0.05) | benign(0.158) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD |
MAP3K2 | SNV | Missense_Mutation | novel | c.219N>C | p.Lys73Asn | p.K73N | Q9Y2U5 | protein_coding | deleterious(0.03) | possibly_damaging(0.735) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
10746 | MAP3K2 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | CI-1040 | CI-1040 | ||
10746 | MAP3K2 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 249565786 |
Page: 1 |